Annual FCF
-$17.00 M
+$5.03 M+22.83%
31 December 2023
Summary:
ReShape Lifesciences annual free cash flow is currently -$17.00 million, with the most recent change of +$5.03 million (+22.83%) on 31 December 2023. During the last 3 years, it has fallen by -$8.06 million (-90.19%). RSLS annual FCF is now -90.19% below its all-time high of -$8.94 million, reached on 31 December 2020.RSLS Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$311.00 K
+$1.05 M+77.08%
30 September 2024
Summary:
ReShape Lifesciences quarterly free cash flow is currently -$311.00 thousand, with the most recent change of +$1.05 million (+77.08%) on 30 September 2024. Over the past year, it has increased by +$2.47 million (+88.81%). RSLS quarterly FCF is now at all-time high.RSLS Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$6.20 M
+$2.47 M+28.49%
30 September 2024
Summary:
ReShape Lifesciences TTM free cash flow is currently -$6.20 million, with the most recent change of +$2.47 million (+28.49%) on 30 September 2024. Over the past year, it has increased by +$11.26 million (+64.50%). RSLS TTM FCF is now at all-time high.RSLS TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RSLS Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +22.8% | +88.8% | +64.5% |
| 3 y3 years | -90.2% | +96.1% | +56.2% |
| 5 y5 years | +38.3% | +92.7% | +69.0% |
RSLS Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -90.2% | +22.8% | at high | +96.1% | at high | +75.4% |
| 5 y | 5 years | -90.2% | +38.3% | at high | +96.1% | at high | +75.4% |
| alltime | all time | -90.2% | +49.9% | at high | +96.8% | at high | +81.7% |
ReShape Lifesciences Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$311.00 K(-77.1%) | -$6.20 M(-28.5%) |
| June 2024 | - | -$1.36 M(-34.5%) | -$8.67 M(-38.1%) |
| Mar 2024 | - | -$2.07 M(-15.7%) | -$14.01 M(-17.6%) |
| Dec 2023 | -$17.00 M(-22.8%) | -$2.46 M(-11.6%) | -$17.00 M(-2.6%) |
| Sept 2023 | - | -$2.78 M(-58.5%) | -$17.45 M(-12.6%) |
| June 2023 | - | -$6.70 M(+32.2%) | -$19.98 M(+1.3%) |
| Mar 2023 | - | -$5.07 M(+74.3%) | -$19.72 M(-10.5%) |
| Dec 2022 | -$22.03 M(+40.1%) | -$2.91 M(-45.2%) | -$22.03 M(-2.6%) |
| Sept 2022 | - | -$5.31 M(-17.5%) | -$22.62 M(-10.2%) |
| June 2022 | - | -$6.43 M(-12.9%) | -$25.20 M(+19.8%) |
| Mar 2022 | - | -$7.38 M(+111.4%) | -$21.03 M(+33.7%) |
| Dec 2021 | -$15.73 M(+75.9%) | -$3.49 M(-55.7%) | -$15.73 M(+11.1%) |
| Sept 2021 | - | -$7.89 M(+248.3%) | -$14.16 M(+91.5%) |
| June 2021 | - | -$2.27 M(+8.9%) | -$7.39 M(-4.9%) |
| Mar 2021 | - | -$2.08 M(+8.2%) | -$7.78 M(-13.0%) |
| Dec 2020 | -$8.94 M(-37.1%) | -$1.92 M(+71.0%) | -$8.94 M(+7.2%) |
| Sept 2020 | - | -$1.12 M(-57.6%) | -$8.34 M(-27.5%) |
| June 2020 | - | -$2.65 M(-18.4%) | -$11.49 M(-2.1%) |
| Mar 2020 | - | -$3.25 M(+145.6%) | -$11.75 M(-17.3%) |
| Dec 2019 | -$14.21 M(-48.4%) | -$1.32 M(-69.1%) | -$14.20 M(-29.0%) |
| Sept 2019 | - | -$4.28 M(+47.6%) | -$20.01 M(-1.5%) |
| June 2019 | - | -$2.90 M(-49.1%) | -$20.31 M(-15.1%) |
| Mar 2019 | - | -$5.70 M(-20.1%) | -$23.92 M(-13.2%) |
| Dec 2018 | -$27.54 M(+11.4%) | -$7.13 M(+55.9%) | -$27.54 M(-6.0%) |
| Sept 2018 | - | -$4.58 M(-29.7%) | -$29.30 M(-3.8%) |
| June 2018 | - | -$6.51 M(-30.2%) | -$30.46 M(+2.9%) |
| Mar 2018 | - | -$9.32 M(+4.9%) | -$29.60 M(+19.7%) |
| Dec 2017 | -$24.73 M(+19.6%) | -$8.89 M(+54.7%) | -$24.73 M(+27.6%) |
| Sept 2017 | - | -$5.75 M(+1.7%) | -$19.37 M(+6.1%) |
| June 2017 | - | -$5.65 M(+27.2%) | -$18.26 M(+0.3%) |
| Mar 2017 | - | -$4.44 M(+25.6%) | -$18.20 M(-11.9%) |
| Dec 2016 | -$20.67 M(-8.7%) | -$3.54 M(-23.7%) | -$20.67 M(-8.1%) |
| Sept 2016 | - | -$4.63 M(-17.1%) | -$22.50 M(-5.9%) |
| June 2016 | - | -$5.59 M(-19.1%) | -$23.90 M(-0.1%) |
| Mar 2016 | - | -$6.91 M(+28.8%) | -$23.92 M(+5.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2015 | -$22.64 M(+16.3%) | -$5.37 M(-11.1%) | -$22.64 M(+4.0%) |
| Sept 2015 | - | -$6.03 M(+7.6%) | -$21.77 M(+8.1%) |
| June 2015 | - | -$5.61 M(-0.6%) | -$20.13 M(+3.2%) |
| Mar 2015 | - | -$5.64 M(+25.6%) | -$19.50 M(+0.2%) |
| Dec 2014 | -$19.47 M(+3.3%) | -$4.49 M(+2.1%) | -$19.47 M(+0.9%) |
| Sept 2014 | - | -$4.40 M(-11.6%) | -$19.30 M(+0.6%) |
| June 2014 | - | -$4.98 M(-11.3%) | -$19.18 M(-1.5%) |
| Mar 2014 | - | -$5.61 M(+29.9%) | -$19.47 M(+3.3%) |
| Dec 2013 | -$18.84 M(-16.5%) | -$4.32 M(+1.0%) | -$18.84 M(-5.9%) |
| Sept 2013 | - | -$4.28 M(-18.8%) | -$20.03 M(-1.0%) |
| June 2013 | - | -$5.27 M(+5.9%) | -$20.23 M(+0.6%) |
| Mar 2013 | - | -$4.98 M(-9.7%) | -$20.11 M(-10.8%) |
| Dec 2012 | -$22.56 M(+11.7%) | -$5.51 M(+23.1%) | -$22.56 M(+0.4%) |
| Sept 2012 | - | -$4.47 M(-13.1%) | -$22.47 M(-3.2%) |
| June 2012 | - | -$5.15 M(-30.6%) | -$23.20 M(+1.7%) |
| Mar 2012 | - | -$7.42 M(+36.7%) | -$22.81 M(+13.0%) |
| Dec 2011 | -$20.19 M(+47.7%) | -$5.43 M(+4.2%) | -$20.19 M(+10.3%) |
| Sept 2011 | - | -$5.21 M(+9.5%) | -$18.30 M(+14.0%) |
| June 2011 | - | -$4.75 M(-0.9%) | -$16.05 M(+8.4%) |
| Mar 2011 | - | -$4.80 M(+35.7%) | -$14.81 M(+8.4%) |
| Dec 2010 | -$13.67 M(-45.0%) | -$3.54 M(+19.4%) | -$13.67 M(-21.4%) |
| Sept 2010 | - | -$2.96 M(-15.7%) | -$17.39 M(-15.0%) |
| June 2010 | - | -$3.51 M(-3.9%) | -$20.47 M(-8.1%) |
| Mar 2010 | - | -$3.66 M(-49.6%) | -$22.27 M(-10.3%) |
| Dec 2009 | -$24.84 M(-26.7%) | -$7.26 M(+20.1%) | -$24.84 M(-8.5%) |
| Sept 2009 | - | -$6.04 M(+13.7%) | -$27.14 M(-8.3%) |
| June 2009 | - | -$5.31 M(-14.7%) | -$29.61 M(-8.5%) |
| Mar 2009 | - | -$6.23 M(-34.9%) | -$32.38 M(-4.5%) |
| Dec 2008 | -$33.91 M(+40.3%) | -$9.56 M(+12.3%) | -$33.91 M(+39.3%) |
| Sept 2008 | - | -$8.51 M(+5.4%) | -$24.35 M(+53.7%) |
| June 2008 | - | -$8.08 M(+4.0%) | -$15.84 M(+104.0%) |
| Mar 2008 | - | -$7.76 M | -$7.76 M |
| Dec 2007 | -$24.17 M(+43.3%) | - | - |
| Dec 2006 | -$16.86 M(+57.2%) | - | - |
| Dec 2005 | -$10.73 M | - | - |
FAQ
- What is ReShape Lifesciences annual free cash flow?
- What is the all time high annual FCF for ReShape Lifesciences?
- What is ReShape Lifesciences annual FCF year-on-year change?
- What is ReShape Lifesciences quarterly free cash flow?
- What is the all time high quarterly FCF for ReShape Lifesciences?
- What is ReShape Lifesciences quarterly FCF year-on-year change?
- What is ReShape Lifesciences TTM free cash flow?
- What is the all time high TTM FCF for ReShape Lifesciences?
- What is ReShape Lifesciences TTM FCF year-on-year change?
What is ReShape Lifesciences annual free cash flow?
The current annual FCF of RSLS is -$17.00 M
What is the all time high annual FCF for ReShape Lifesciences?
ReShape Lifesciences all-time high annual free cash flow is -$8.94 M
What is ReShape Lifesciences annual FCF year-on-year change?
Over the past year, RSLS annual free cash flow has changed by +$5.03 M (+22.83%)
What is ReShape Lifesciences quarterly free cash flow?
The current quarterly FCF of RSLS is -$311.00 K
What is the all time high quarterly FCF for ReShape Lifesciences?
ReShape Lifesciences all-time high quarterly free cash flow is -$311.00 K
What is ReShape Lifesciences quarterly FCF year-on-year change?
Over the past year, RSLS quarterly free cash flow has changed by +$2.47 M (+88.81%)
What is ReShape Lifesciences TTM free cash flow?
The current TTM FCF of RSLS is -$6.20 M
What is the all time high TTM FCF for ReShape Lifesciences?
ReShape Lifesciences all-time high TTM free cash flow is -$6.20 M
What is ReShape Lifesciences TTM FCF year-on-year change?
Over the past year, RSLS TTM free cash flow has changed by +$11.26 M (+64.50%)